Acorn Biolabs

Acorn Biolabs

Acorn Biolabs is a biotechnology company offering long-term human cell cryopreservation.

Acorn Biolabs is a company that looks to provide genetic engineering technologies that can prolong the human life span. The company was founded by Drew Taylor in 2017, in Kitchener, Ontario, Canada.

The company looks to develop methods of cryopreservation through means such as stem cell storage, cell and gene therapy, bio banking, and stem cell collection. The service that Acorn Biolabs offers is to freeze a patient's cells for the purpose of fighting diseases in the future.

The company is able to transform any cell into a stem cell, preserve the cells in order to provide personal regenerative medicines, and is able to do so through the collection of a few hairs. The process includes reprogramming adult cells into stem cells. They are able to grow tissues, and 3D print organs. However, freezing the cells allows the company to use them for a specific use case in the future.

Acorn Biolabs has held over one-thousand clinical trials and has sixty-thousand patients enrolled with the goal of tackling diseases like Alzheimer's or diabetes, healing injuries anywhere in the body, regrowing skin, repairing sight, providing 3D printed implant organs, and more.

Timeline

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Acorn Biolabs funding round, January 2019
January 2019
3 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Drew Taylor

Founder

Patrick Pumputis

Founder

Steven ten Holder

Founder

Further reading

Title
Author
Link
Type
Date

Cryopreservation company, Acorn Biolabs closes $3.3M seed funding and ramps towards consumer launch

Acorn Biolabs

Web

Documentaries, videos and podcasts

Title
Date
Link

Acorn Biolabs

July 6, 2018

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Jonathan Shieber
Invalid Date
TechCrunch
Acorn Biolabs wants consumers to pay them to store genetic material in a bet that the increasing advances in targeted genetic therapies will yield better healthcare results down the line. The company's pitch is to "Save young cells today, live a longer, better, tomorrow." It&#8217...

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.